Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 2
2007 pubmed

Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat.

Xu. Xiangbin X; Pang. Jinjiang J; Yin. Hongchao H; Li. Meixiu M; Hao. Wei W; Chen. Chen C; Cao. Ji-Min JM

Key Findings

  • Hexarelin (10⁻⁷ M) blocked angiotensin‑II‑driven fibroblast growth and collagen making in rat heart cells
  • It reduced both TGF‑beta mRNA levels and the release of active TGF‑beta1 from these cells
  • The anti‑fibrotic effect required activation of the growth‑ hormone secretagogue receptor and the adenosine A₂ receptor, raising cellular cAMP

Practical Outcomes

  • The results suggest hexarelin might have heart‑protective, anti‑fibrotic properties, but the evidence is limited to rat cells in a dish. No human dosing or safety data are provided, so it isn’t ready for personal use or protocol design. More animal and clinical studies are needed before biohackers could consider it for heart health.

Summary

In a lab study using heart cells from newborn rats, the synthetic peptide hexarelin was shown to slow down the cells that cause scar tissue in the heart and cut down the production of collagen, a key component of that scar tissue. It does this by lowering a growth factor called TGF‑beta and working through specific receptors, but the work was done only in cell dishes, not in people.

Abstract

Abnormal growth of cardiac fibroblasts is critically involved in the pathophysiology of cardiac hypertrophy/remodeling. Hexarelin is a synthetic growth hormone secretagogue (GHS), which possesses a variety of cardiovascular protective activities mediated via the GHS receptor (GHSR), including improving cardiac dysfunction and remodeling. The cellular and molecular mechanisms underlying the effect of GHS on cardiac fibrosis are, however, not clear. In this report, cultured cardiac fibroblasts from 8-day-old rats were stimulated with ANG II or FCS to induce proliferation. The fibroblast proliferation and DNA and collagen synthesis were evaluated utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, (3)H-thymidine incorporation, and (3)H-proline incorporation. The level of mRNA of transforming growth factor (TGF)-beta was evaluated by RT-PCR, and the active TGF-beta1 release from cardiac fibroblasts was evaluated by ELISA. The level of cellular cAMP was measured by radioimmunoassay. In addition, the effects of 3,7-dimethyl-l-propargylxanthine (DMPX; a specific adenosine receptor A(2)R antagonist) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; a specific A(1)R antagonist) were tested. It was found that incubation with 10(-7) mol/l hexarelin for 24 h 1) inhibited the ANG II-induced proliferation and collagen synthesis and the 5% FCS- and TGF-beta-induced increase of DNA synthesis in cardiac fibroblast and 2) reduced ANG II-induced upregulation of TGF-beta mRNA expression and active TGF-beta1 release from fibroblasts. Hexarelin increased the cellular level of cAMP in cardiac fibroblasts. DMPX (10(-8) mol/l) but not DPCPX abolished the effect of hexarelin on cardiac fibroblast DNA synthesis. It is concluded that hexarelin inhibits DNA and collagen synthesis and proliferation of cardiac fibroblasts through activation of both GHSR and A(2)R and diminishment of ANG II-induced increase in TGF-beta expression and release.

Study Information

Provider

pubmed

Year

2007

Date

2007-08-31T00:00:00.000Z

DOI

10.1152/ajpheart.00004.2007